Affiliation: University of Chicago
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 StudyRita Nanda
Rita Nanda, University of Chicago, Chicago, IL Laura Q M Chow, University of Washington, Seattle, WA E Claire Dees, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC Raanan Berger, Sheba Medical Center, Tel Hashomer Ravit Geva, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel Shilpa Gupta, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL Lajos Pusztai, Yale University School of Medicine, New Haven, CT Kumudu Pathiraja, Gursel Aktan, Jonathan D Cheng, and Vassiliki Karantza, Merck and Co, Kenilworth, NJ and Laurence Buisseret, Universite Libre de Bruxelles, Bruxelles, Belgium
J Clin Oncol 34:2460-7. 2016..We assessed the safety and antitumor activity of the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab in patients with advanced TNBC...
- "Targeting" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancersRita Nanda
Department of Medicine, The University of Chicago, Chicago, IL 60637 1470, USA
Semin Oncol 38:254-62. 2011..This review focuses on our current understanding of the clinicopathological features of TNBC, therapeutic options and ongoing research efforts...
- Targeting the human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer: recent advances and future directionsRita Nanda
Section of Hematology Oncology, Department of Medicine, University of Chicago, USA
Rev Recent Clin Trials 2:111-6. 2007....
- Advances in breast cancer: pathways to personalized medicineOlufunmilayo I Olopade
Department of Medicine, Section of Hematology Oncology, Center for Clinical Cancer Genetics, University of Chicago, Chicago, Illinois 60637, USA
Clin Cancer Res 14:7988-99. 2008..The five articles in this edition of CCR Focus highlight recent advances and future directions on the pathway to individualized approaches for the early detection, treatment, and prevention of breast cancer...
- Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancerDezheng Huo
Center for Clinical Cancer Genetics and Global Health, Department of Medicine, Section of Hematology Oncology, University of Chicago, 5841 S Maryland Ave, MC 2115, Chicago, IL 60637, USA
J Clin Oncol 27:4515-21. 2009..In the first study of its kind, we determined the distribution of molecular subtypes of invasive breast tumors in indigenous black women in West Africa...
- Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancersMinjie Wei
Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637 1463, USA
Breast Cancer Res Treat 111:113-20. 2008..These data suggest that unlike FANCF, both ER and BRCA1 are specifically targeted for methylation in sporadic breast cancers, a phenomenon that should be explored for development of novel diagnostic and therapeutic approaches...
- The role of tumor-associated macrophages in breast cancer progression (review)Elias Obeid
Section of Hematology Medical and Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA
Int J Oncol 43:5-12. 2013..Given the multiple roles of TAMS in breast cancer progression and metastasis, therapies targeting these cells are in development and demonstrate promising results...
- Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography INancy U Lin
Nancy U Lin, Hao Guo, Nicole Ryabin, Julie S Najita, William T Barry, Ian E Krop, Eric P Winer, and Annick D Van den Abbeele, Dana Farber Cancer Institute Andrea L Richardson and Annick D Van den Abbeele, Brigham and Women s Hospital, Boston, MA Jeffrey T Yap, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT Ingrid A Mayer and Carlos L Arteaga, Vanderbilt Ingram Cancer Center, Nashville, TN Carla I Falkson, University of Alabama, Birmingham, AL Timothy J Hobday, Mayo Clinic, Rochester, MN E Claire Dees, University of North Carolina, Chapel Hill, NC Rita Nanda, University of Chicago, Chicago, IL Mothaffar F Rimawi, Baylor College of Medicine, Houston, TX and Antonio C Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
J Clin Oncol 33:2623-31. 2015..We tested the combination in the earlier-line setting and explored the predictive value of [(18)F]fluorodeoxyglucose positron emission tomography ([(18)F]FDG-PET) for clinical outcomes...
- A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancerRita Nanda
Section of Hematology Oncology, Department of Medicine, The University of Chicago, 5841 S Maryland Ave, MC 2115, Chicago, IL 60637 USA 5841 S Maryland Ave, MC 2115, Chicago, IL 60637 1470 USA
Springerplus 5:947. 2016..GR antagonism with mifepristone increases chemotherapy-induced breast cancer cell death, therefore we conducted a phase I clinical trial of mifepristone and nab-paclitaxel in advanced breast cancer...
- The molecular portraits of breast tumors are conserved across microarray platformsZhiyuan Hu
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
BMC Genomics 7:96. 2006..To overcome this problem we used publicly available breast cancer gene expression data sets and a novel approach to data fusion, in order to validate a new breast tumor intrinsic list...
- Phenotypic evaluation of the basal-like subtype of invasive breast carcinomaChad A Livasy
Department of Pathology and Lab Medicine, University of North Carolina, Chapel Hill, NC 27599 7525, USA
Mod Pathol 19:264-71. 2006..These findings should further assist in the identification of basal-like carcinomas in clinical specimens, facilitating treatment and epidemiologic studies of this tumor subtype...
- BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomyMinjie Wei
Center for Clinical Cancer Genetics, Department of Medicine, University of Chicago, Chicago, Illinois 60637 1463, USA
Cancer Res 65:10692-9. 2005..Our data support a model of carcinogenesis in which BRCA1 promoter methylation may serve as a "first hit," much like an inherited germ line mutation, and promote tumor progression down a restricted set of molecular pathways...
- Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestryRita Nanda
Center for Clinical Cancer Genetics, Section of Hematology Oncology, Department of Medicine, University of Chicago Medical Center, Chicago, Ill 60637 1470, USA
JAMA 294:1925-33. 2005..Ten years after BRCA1 and BRCA2 were first identified as major breast cancer susceptibility genes, the spectrum of mutations and modifiers of risk among many ethnic minorities remain undefined...
- A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignanciesDavid S Shames
Hamon Center for Therapeutic Oncology Research, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States of America
PLoS Med 3:e486. 2006....